P39 ASSOCIATION OF NOCTURNAL HYPOXIA AND CLINICAL STATUS IN CHILDHOOD CYSTIC FIBROSIS

1DS Urquhart, 1S Stanojevic, 1A Laverty, 1D Odendaal, 1G Derrick, 1E Scrase, 1M Bryan, 1JE Williams, 1H Montgomery, 1N Narang, 1A Jaffe, 2Royal Hospital for Sick Children, Edinburgh, UK; 2Institute of Child Health, London, UK; 3Great Ormond Street Hospital, London, UK; 4Hospital for Sick Children, Toronto, Canada; 5Sydney Children's Hospital, Sydney, Australia

doi:10.1136/thx.2009.127159b

Hypoxia in cystic fibrosis (CF) occurs with sleep, exercise, chest exacerbations and air travel. Hypoxia may modulate growth, the pulmonary circulation, quality of life and also lung inflammation, which may in turn affect lung function and exercise capacity. The study aimed to delineate the association of nocturnal hypoxia and clinical status in childhood CF.

41 children (21 girls) with CF each underwent home oximetry. Hypoxia was defined as SaO2 <93% for >10% sleep time. Spirometry, exercise testing with oxygen uptake (V\textsubscript{O\textsubscript{2}}) measures, bone densitometry of lumbar spine (BMAD), quality of life assessment using the CFQ-UK questionnaire, Chrispin-Norman (CNS) scoring of chest radiographs and measurement of inflammatory markers (full blood count, serum interleukin 8) were performed. Mann-Whitney tests were used for intergroup comparisons.

Hypoxia was detected in 9/41 subjects. Hypoxic subjects were older with median (IQR) age of 14.9 (12.4, 15.6) vs 12.2 (10, 13.7) in normoxic subjects (p<0.05) and had lower body mass index (−1.1 (−2, −0.6) vs −0.2 (−0.7, +0.3); p<0.01). Hypoxic subjects had lower forced expiratory volume in 1 s (−5.9 (−3.5, −4.7) vs −1.7 (−2.5, −0.4); p<0.001) and forced vital capacity (−2.6 (−3.8, −1.3) vs −0.6 (−1.8, +0.1); p<0.001) z-scores, increased residual volume/total lung capacity ratio (0.5 (0.45, 0.64) vs 0.52 (0.24, 0.45) p<0.001), higher CNS (16 (12, 19) vs 10 (7, 15); p = 0.002), lower peak V\textsubscript{O\textsubscript{2}} (28.8 (24, 34.2) vs 35.3 (33.8, 43.2) ml/kg/min; p = 0.01) and reduced CFQ-UK scores (62 (45, 70) vs 74 (66, 88); p = 0.05). Hypoxic subjects had higher neutrophil counts (8.3 (4.8, 13) vs 3.2 (2.5, 4.6) x10\textsuperscript{9}/ml; p<0.001) and interleukin 8 levels (10.8 (4.4, 25.7) vs 5.1 (3.6, 9) pg/ml; p<0.05), more intravenous antibiotic courses in the preceding year (4 (2.5, 4) vs 0 (0, 1); p<0.001) and reduced BMAD z-scores (−1.4 (−1.8, −0.4) vs −0.3 (−1, +0.7); p = 0.05).

While hypoxia may be a casual mechanism for worsening clinical and inflammatory status, it may simply be a surrogate marker of disease severity. Future research should aim to delineate the role of hypoxia in CF, elucidating effector mechanisms by which hypoxia mediates CF lung disease and also the extent to which restoration of normoxia (by oxygen therapy or non-invasive ventilation) impacts on the CF lung.

COPD exacerbations

P94 USE ANDUTILITY OF A 24-HOUR INFORMED TELEPHONE SUPPORT SERVICE FOR “HIGH-RISK” PATIENTS WITH COPD


doi:10.1136/thx.2009.127159p

Introduction The “epidemic” of chronic obstructive pulmonary disease (COPD) requires innovative service developments to improve outcomes. It is particularly important to prevent hospitalisations. Successful chronic care models in COPD have been described. We present the first evaluation of an Early Presentation and Intervention in COPD (EPIC) service focused on “informed” 24/7 telephone support for high-risk NHS COPD patients. The service was funded by a Clinical Innovations competition at Royal Free Hampstead NHS Trust.

Method 74 “high-risk” patients were recruited over 6 months (defined as GOLD stage IV or those with previous hospitalisation) from inpatient and outpatient settings, representing 32% of patients admitted over that period. After a recruitment interview to record key patient and COPD information, patients were contacted every 2 months by a nurse and reviewed in clinic 6-monthly. Patients were invited to use the telephone service “when you need any advice about your chest and particularly if you think you are having a flare-up”. We present the use and utility of the service over 1 year.

Results The 74 patients were high-risk (eg, mean (SD) age 70.3 (9.1) years, forced expiratory volume in 1 s 442 (16.5)%). 50% were on long-term oxygen therapy and 46% lived alone. 70% of patients completed 1 year, 23% died and 7% left. Follow-up was for a total of 22074 days. 76% of patients used the service or it was used on their behalf, generating 255 calls (mean duration 7.9 min) at a rate of 1 call/100 patients/day. 76% of calls were between 08.00 h and 17.00 h. The proportion of calls in response to possible exacerbation did not vary by day, but was higher overnight and at weekends. There were very few overnight calls, most of which required further assistance from emergency services. To avoid one hospital assessment overnight, the service would require 7359 patients. The 52 patients completing 1 year had a reduced number and duration of hospitalisations while on the service compared with the previous year (31 vs 56 admissions and 289 vs 461 days, both p = 0.002). The patients valued the service.

Conclusion A telephone advice line for high-risk COPD patients reduces hospitalisation and is valued by patients, but is unlikely to be cost-effective 24/7 at a local level given the low volume of overnight calls.

P95 EFFECT OF TELEPHONE WEATHER ALERT SYSTEM ON EMERGENCY COPD ADMISSIONS AND HEALTHCARE UTILISATION IN PATIENTS WITH MILD TO MODERATE AIRFLOW OBSTRUCTION

NDiary Bakerly, A Thompson, JA Roberts. Salford PCT, Salford, Lancashire, UK

doi:10.1136/thx.2009.127159q

Introduction Exacerbations are a major cause of morbidity and mortality in patients with chronic obstructive pulmonary disease (COPD). They have a great impact on patients’ health, as well as having a large impact on healthcare utilisation (HCU) including emergency hospital admissions. They are more frequent in the winter months, and it has been hypothesised that they are positively linked with a sudden drop in temperature.

Aims To evaluate the effectiveness of a telephonic alert system (the Met Office project) to warn patients with COPD of severe weather changes on hospital admissions and HCU.

Methods All patients with mild to moderate airflow obstruction from three primary care practices were invited to participate. The project ran between 1 November 2008 and 28 March 2009. Weather alerts were delivered to patients via automated message by the Met Office. The primary outcome was number of emergency COPD admissions. Secondary outcomes were hospital bed-days, general practice consultations (surgery visits and telephone advice), home visits, visits to A&E, visits by COPD early supported discharge (ESD) team and out-of-hours service were measured during the project and compared (for the same patients) with the same data between 1 November 2007 and 28 March 2008 (12 months earlier).

Results A total of 455 patients were invited to participate and 157 (34%) patients took part in the project. Mean (SD) age 71 (9.7) years, forced expiratory volume in 1 s (FEV\textsubscript{1}) 1.4 (0.5) l and 59.1 (16.5)% predicted. During the project five weather alerts were generated (first alert reached 150 patients; second reached 146; third reached 138 patients; fourth reached 137 patients; and the fifth reached 125 patients). Data on hospital admissions and HCU are
A health forecasting service may reduce exacerbation rates. The methodology was viewed positively by patients and showed that...
Poster sessions

P98 RETROSPECTIVE ANALYSIS OF PREDICTORS OF MORTALITY AND READMISSION AFTER AN EXACERBATION OF COPD

A Fahim, W Lee, S Faruqi, JA Kastelik. Castlehill Hospital, Cottingham, East Yorkshire, UK
doi:10.1136/thx.2009.127159t

Introduction and Objectives Patients who survive an acute exacerbation of COPD (AECOPD) are at increased risk of death and rehospitalisation. The aim of this study was to identify predictors of mortality and readmission in patients admitted with an AECOPD.

Methods We retrospectively reviewed 402 episodes in 205 patients admitted to our hospital with an AECOPD from April 2005 to June 2009. Forced expiratory volume in 1 s (FEV1)%, number of admissions in the last 12 months, current medications, MRC dyspnoea scale, performance status (PS), co-morbidities, social circumstances, total white cell count (WCC), C-reactive protein (CRP), smoking status and demographic parameters were obtained and analysed.

Results One hundred and six men of median age 69 years (range 47–93) with 225 episodes and 99 women of median age 72 years (range 49–91) with 178 episodes comprised the study population. Overall, 42% had two or more admissions in the previous 12 months. 67% had an FEV1 <50% of predicted and 65% had an MRC dyspnoea scale ≥3; 46% had a PS ≥3 and 31% had two or more co-morbidities; 62% of patients were on a combination of inhaled steroids and long-acting β2 agonist and 45% were on an anti-cholinergic agent; 24% lived alone and 43% continued to smoke. Cumulative mortality was 6.8%. Of those patients, 55% had ≥2 admissions in 12 months, 69% had an MRC dyspnoea scale ≥3, 55% continued to smoke, 62% had a PS ≥3 and 62% had two or more co-morbidities. We found social isolation to be the only significant predictor of mortality. The factors associated with increased risk of readmission included lower FEV1%, and continuing to smoke.

Conclusion Our study suggests that mortality and readmissions in patients admitted with an AECOPD are multifactorial. Social isolation appears to be associated with an increased risk of death. These findings need to be confirmed in a larger prospective study.

P99 CHANGES IN PLASMA COTININE AT EXACERBATION AND FASTER EXACERBATION RECOVERY IN NON-SMOKERS IN COPD

1GC Donaldson, 1JK Quint, 2D Powrie, 1R West, 1JA Wedzicha. 1University College London, London, UK; 2Southend University Hospital, Southend, UK
doi:10.1136/thx.2009.127159u

Introduction The benefits of not smoking on survival, lung function and risk of hospital admission are well established in chronic obstructive pulmonary disease (COPD). Patient self-reporting of tobacco use can be unreliable due to its social unacceptability. We investigated whether acute exacerbations of COPD differed between smoking and non-smoking patients.

Methods Seventy-two patients had plasma collected at baseline and exacerbation in which cotinine was measured by capillary column gas-liquid chromatography. Exacerbations were defined as two consecutive days of two or more respiratory symptoms, of which one was increased dyspnoea, sputum purulence or sputum volume; a few were identified by questioning the patients about treatment by their general practitioner or hospital doctor. Blood samples were taken 3.7 days (SD 2.5) after onset. Exacerbation recovery was determined as the number of days after onset that symptoms persisted and was followed by two consecutive days clear of symptoms. A smoker was defined as having a baseline cotinine concentration >15 ng/ml.

Results The 72 patients had a mean (SD) age of 69.5 (8.9) years, forced expiratory volume in 1 s (FEV1) 52.4 (17.0)% predicted and a median 2.79 (IQR 1.1–5.6) exacerbations per year. Plasma cotinine fell significantly in 72 patients (Wilcoxon; p = 0.022) and in smokers in particular from 223 ng/ml (IQR 156–345) to 190.0 ng/ml (IQR 115–304); p = 0.014, fig 1). Recovery times from exacerbation were available for 65 exacerbations; data were missing because the exacerbation took longer than 30 days to recovery or no symptoms were recorded post onset. Smokers took a median 14.5 days (IQR 8.5–25; n = 32) to recover which was significantly longer than in non-smokers who took 10 days (IQR 6–16; n = 33; p = 0.041). There was no difference between smokers whose cotinine fell at exacerbation (median 15 days (IQR 10–27); n = 21) and those in whom cotinine increased (median 14 days (IQR 6–18); n = 11; p = 0.393).

Conclusion Patients with COPD reduce their smoking during exacerbation which can provide a window of opportunity to target smoking cessation advice. Exacerbations of COPD may be shorter if the patient does not currently smoke.

P100 SPUTUM BACTERIOLOGY IN ACUTE EXACERBATION OF COPD: UTILITY OF SPUTUM APPEARANCE AND PREVIOUS CULTURE RESULTS IN DETERMINING ANTIBIOTIC THERAPY

W Shafiq, G Antunes, S Murphy. James Cook University Hospital, Middlesbrough, UK
doi:10.1136/thx.2009.127159v

Background Acute exacerbations of COPD (AECOPD) are predominantly non-infective or viral in origin and most patients are probably treated with antibiotics unnecessarily. It is recommended that sputum appearance is used as a guide to determine the need for antibiotic therapy.

Aim The purpose of this study was to describe the bacteriology of AECOPD and to determine the utility of sputum inspection and previous sputum bacteriology history in predicting the need for and choice of antibiotics in AECOPD.

Methods Patients admitted to James Cook University Hospital (JCUH) with AECOPD (June–Dec 2007) were identified and the hospital microbiology database reviewed. Sputum microbiology results for the index episode and previous episodes of AECOPD were included. The relationship between sputum appearance and culture result and the impact of positive sputum culture on antibiotic choice was examined.

Results There were 226 AECOPD episodes in 81 patients. Sputum samples were obtained in 82.7% and were described as mucoid (MU) 9.1%, mucopurulent (MP) 63.6% and purulent (PU) 27.2%.

Abstract P99 Figure 1
Pathogens were isolated in 29.5% and frequency varied according to sputum appearance: MU 8%, MP 29.4%, PU 54.9% (odds ratio (OR) PU:MU 13.4 (1.56–298), p<0.005, MP:PU 2.92 (1.4–6.1), p<0.005. For 52 patients with >2 exacerbations, previous sputum culture results were predictive of subsequent culture results (pathogen isolated if previous sputum positive 60.6% vs previous sputum negative 21.9%; OR 5.48 (2–14.8), p<0.005). 73% of pathogenic organisms were isolated (H influenzae 38.2%, Pseudomonas 24.6%, S pneumoniae 22%, E.coli 11%, other 4%). The same organism was isolated in successive episodes in 57.5% (19/33) of which antibiotic sensitivities were identical in 84.2% (16/19).

**Conclusions** Bacterial infection in AECOPD may be predicted by inspection of sputum and previous sputum bacteriology. Antibiotics should be prescribed for AECOPD only if purulent sputum is obtained or if pathogenic bacteria were isolated from sputum in previous episode. The commonest pathogen isolated in AECOPD is H influenzae followed by Pseudomonas and S pneumoniae. Antibiotic therapy in AECOPD should be guided by previous sputum bacteriology if available.

**P101** VITAMIN D LEVELS AND SUSCEPTIBILITY TO HUMAN RHINOVIRUS EXACERBATIONS OF COPD

1JK Quant, 1GC Donaldson, 1JP Goldberg, 1A Patel, 1S Karmali, 1N Wassef, 1M Thomas, 1JA Wadichha. 1University College London, London, UK; 1Royal Free NHS Trust, London, UK

doi:10.1136/thx.2009.127159w

**Background** Human rhinovirus (HRV) is the commonest virus associated with exacerbations of chronic obstructive pulmonary disease (COPD). It has been postulated that vitamin D deficiency increases infection susceptibility. We investigated whether vitamin D deficiency was associated with increased susceptibility to HRV exacerbations in COPD and whether vitamin D levels change from baseline to exacerbation.

**Methods** We studied 56 COPD patients (32 men) of mean (SD) age 64 (9.2) years, forced expiratory volume in 1 s (FEV1) 50.9 (20.5)%

**Results** (major and/or minor) for two consecutive days.

**Conclusions** Patients with lower vitamin D levels do not more likely to be HRV positive at exacerbation and exacerbation levels of vitamin D do not correlate with HRV load. Vitamin D levels do not decrease at exacerbation in COPD. Funded by NIH RO1 HL082578.

**P102** CONCURRENT COPD/PNEUMONIA: INCIDENCE AND CLINICAL OUTCOMES AMONG PATIENTS ADMITTED WITH EXACERBATION

1N Ahmad, 1S George, 1E Davis, 1KS Srinivasan, 1H Moudgil, 1Princess Royal Hospital, Telford, UK; 1Princess Royal Hospital and University of Keele Medical School, Telford, UK

doi:10.1136/thx.2009.127159x

**Background** Although infection is frequently implicated in exacerbations of chronic obstructive pulmonary disease (COPD), the actual reporting of concurrent pneumonia is more variable and anecdotally can be subjective. Despite similar clinical outcomes, the 2008 RCP/BTS National Audit identified a disproportionately higher than expected reporting of concurrent pneumonia among patients admitted with COPD at this hospital.

**Objectives** More robustly correlating with radiology reported data on COPD admissions, objectives were (1) to report the actual incidence of concurrent COPD/pneumonia among admissions coded as exacerbation and (2) to determine in which way this then influences clinical outcomes.

**Methods** Retrospective data including formal radiology reporting of admissions over 12 months to end December 2008 were analysed ranking non-parametric data (Mann-Whitney U) or ratios by χ² reporting statistical significance where p < 0.05. Pneumonia scoring and formal microbiology were not assessed.

**Results** Of 784 admissions, 570 (72.7%) were primarily respiratory related and, of these, 199 (25%) had radiological evidence for pneumonia. The group with pneumonia (n = 199) tended to have longer length of stay (median 7 (interquartile range 3–14) vs 6 (3–10) days, p = 0.005), to be older (77 (69–82) vs 71 (63–79) years, p = 0.001), featured more men (54% vs 44%, p = 0.021) and were less likely to have supported early discharge (17% vs 26%, p = 0.044) than those without pneumonia (n = 581). Importantly, despite no difference in the mean number of admissions during this period, the group with pneumonia also reported more inpatient mortality (22/199 vs 15/571, p = 0.001).

**Conclusions** The data identified that about one-third of patients admitted with COPD at this hospital have radiology-reported evidence of concurrent pneumonia and an at risk of older men who then also share worse clinical outcomes including longer length of stay and inpatient mortality.

**P103** BIOLOGICAL, PHYSIOLOGICAL AND SUBJECTIVE BIOMARKERS IN COPD SUBJECTS AT STABLE STATE AND EXACERBATION: AN OBSERVATION

1M Rafadhel, 1S Terry, 1S McKenna, 1V Misty, 1C Reid, 1M McCormick, 2P Rugman, 2P Dodson, 1M Saunders, 1ID Pavord, 1CE Brightling, 1Institute of Lung Health, University of Leicester, Leicester, UK; 2AstraZeneca, Charnwood, Loughborough, UK

doi:10.1136/thx.2009.127159y

**Introduction** Pulmonary and systemic inflammation is present in patients with chronic obstructive pulmonary disease (COPD) during periods of stability, with increased inflammation, worsened lung function and health status during exacerbations. Current management of exacerbations includes oral corticosteroids and antibiotics if there is an associated increase in sputum purulence. The effect of different aetiologies during an exacerbation may give rise to different inflammatory responses, and thus may provide a biomarker platform for aetiological diagnosis, targeted therapy and/or inflammatory modulation in a heterogeneous disease.

**Aims** To assess biological, physiological and subjective biomarkers in subjects with COPD during stable state and exacerbations.
Abstract P103 Table 1 Baseline demographic data of subjects

<table>
<thead>
<tr>
<th></th>
<th>Women</th>
<th>Men</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>N</strong></td>
<td>44</td>
<td>101</td>
</tr>
<tr>
<td><strong>Age</strong></td>
<td>67 (43–84)</td>
<td>69 (45–88)</td>
</tr>
<tr>
<td><strong>Ex-smokers (%)</strong></td>
<td>68</td>
<td>69</td>
</tr>
<tr>
<td><strong>Current smokers (%)</strong></td>
<td>30</td>
<td>29</td>
</tr>
<tr>
<td><strong>Pack year history</strong></td>
<td>37 (10–100)</td>
<td>54 (10–153)</td>
</tr>
<tr>
<td><strong>Exacerbation rate prior to study entry</strong></td>
<td>4 (1–12)</td>
<td>3 (1–12)</td>
</tr>
<tr>
<td><strong>BMI (kg/m²)</strong></td>
<td>27 (1.0)</td>
<td>26 (0.4)</td>
</tr>
<tr>
<td><strong>FFMI (kg/m²)</strong></td>
<td>16 (0.7)</td>
<td>18 (0.2)</td>
</tr>
<tr>
<td><strong>FEF₂₅/₇₅ (%)</strong></td>
<td>55 (2)</td>
<td>48 (2)</td>
</tr>
<tr>
<td><strong>FEV₁ (%)</strong></td>
<td>57.2 (3.1)</td>
<td>50.0 (2.0)</td>
</tr>
<tr>
<td><strong>Reversibility (ml)</strong></td>
<td>52 (1–100–250)</td>
<td>45 (500–500)</td>
</tr>
<tr>
<td><strong>Kco (%) predicted</strong></td>
<td>55 (3)</td>
<td>57 (3)</td>
</tr>
<tr>
<td><strong>Ko (%) predicted</strong></td>
<td>69 (4)</td>
<td>69 (3)</td>
</tr>
<tr>
<td><strong>Long-acting (β agonist (%)</strong></td>
<td>75</td>
<td>76</td>
</tr>
<tr>
<td><strong>Inhaled corticosteroid use</strong></td>
<td>86</td>
<td>86</td>
</tr>
<tr>
<td><strong>Inhaled corticosteroid dose (µg)</strong></td>
<td>1250 (123)</td>
<td>1362 (81)</td>
</tr>
<tr>
<td><strong>Maintenance prednisolone (%)</strong></td>
<td>2</td>
<td>7</td>
</tr>
<tr>
<td><strong>Prednisolone dose (mg)</strong></td>
<td>10 (10)</td>
<td>5 (4–10)</td>
</tr>
<tr>
<td><strong>CRP (mg/l)</strong></td>
<td>2.5 (6.5)</td>
<td>6.0 (10.5)</td>
</tr>
<tr>
<td><strong>Sputum neutrophils (%)</strong></td>
<td>69.2 (3.7)</td>
<td>68.3 (2.3)</td>
</tr>
<tr>
<td><strong>Sputum eosinophils (%)</strong></td>
<td>1.2 (0.7 to 2.2)</td>
<td>1.2 (0.9 to 1.7)</td>
</tr>
</tbody>
</table>

Methods 145 subjects with COPD (GOLD I–IV) entered a 12-month longitudinal study looking at biomarkers at stable state (3-monthly visits) and exacerbations (table 1). Health status was measured using the chronic respiratory health questionnaire (CRQ) and the visual analogue score (VAS). Spirometry was undertaken pre and post salbutamol bronchodilation, while spontaneous/induced sputum and blood were processed and analysed for cellular differential and free supernatants using the meso-scale platform (MDS, Maryland, USA) which included 26 cytokines and chemokines (inflammatory panel), growth factors and acute phase reactants (vascular/hypoxia panel). Neopterin (serum and sputum) was measured using ELISA and PCT (serum) was measured using the chronic respiratory health questionnaire (CRQ) and the visual analogue score (VAS). Spirometry was undertaken pre and post salbutamol bronchodilation, while spontaneous/induced sputum and blood were processed and analysed for cellular differential and free supernatants using the meso-scale platform (MDS, Maryland, USA) which included 26 cytokines and chemokines (inflammatory panel), growth factors and acute phase reactants (vascular/hypoxia panel). Neopterin (serum and sputum) was measured using ELISA and PCT (serum) was measured using the Kryptor platform (BRAHMS, Germany).

Results 145 baseline visits and 182 exacerbations were captured. The mortality rate was 9% during the study. Comparing stable state and exacerbations (table 1). Health status was measured using the chronic respiratory health questionnaire (CRQ) and the visual analogue score (VAS). Spirometry was undertaken pre and post salbutamol bronchodilation, while spontaneous/induced sputum and blood were processed and analysed for cellular differential and free supernatants using the meso-scale platform (MDS, Maryland, USA) which included 26 cytokines and chemokines (inflammatory panel), growth factors and acute phase reactants (vascular/hypoxia panel). Neopterin (serum and sputum) was measured using ELISA and PCT (serum) was measured using the Kryptor platform (BRAHMS, Germany).

Conclusions In subjects with COPD there is a measurable increase in systemic and pulmonary inflammation during an exacerbation and an associated decline in health status and lung function. Whether these biomarkers increase differentially in response to different aetiologies needs further investigation.

Abstract P104 Table 1 Clinical characteristics at admission

<table>
<thead>
<tr>
<th></th>
<th>Pneumonia (n = 64)</th>
<th>COPD (n = 163)</th>
<th>Asthma (n = 57)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibiotics given (%)</strong></td>
<td>100</td>
<td>76</td>
<td>58</td>
</tr>
<tr>
<td><strong>Oral antibiotics (%)</strong></td>
<td>94</td>
<td>75</td>
<td>57</td>
</tr>
<tr>
<td><strong>Intravenous antibiotics (%)</strong></td>
<td>67</td>
<td>18</td>
<td>10</td>
</tr>
<tr>
<td><strong>Oral corticosteroid therapy (%)</strong></td>
<td>31</td>
<td>87</td>
<td>91</td>
</tr>
<tr>
<td><strong>Blood leucocytes (×10⁵ cells/l)</strong></td>
<td>14.1 (7.5)</td>
<td>10.1 (4.9)</td>
<td>10.8 (4.4)</td>
</tr>
<tr>
<td><strong>Blood neutrophils (×10³ cells/l)</strong></td>
<td>12.4 (7.1)</td>
<td>7.5 (4.8)</td>
<td>7.7 (4.4)</td>
</tr>
<tr>
<td><strong>C-reactive protein (mg/l)</strong></td>
<td>187 (158)</td>
<td>17 (34)</td>
<td>9 (21)</td>
</tr>
<tr>
<td><strong>Procalcitonin (ng/ml)</strong></td>
<td>1.25 (2.90)</td>
<td>0.05 (0.07)</td>
<td>0.03 (0.04)</td>
</tr>
</tbody>
</table>

*Median (interquartile range).
COPD exacerbations

Thorax 2009 64: A114-A118

Updated information and services can be found at:
http://thorax.bmj.com/content/64/Suppl_4/A114

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Emergency medicine (185)
- Epidemiologic studies (1829)
- General practice / family medicine (339)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/